Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557650 | 0.83 | HDAC8 (0.44) | PLA2G2ACYP2C9CYP2C19HDAC8CYP1A2 | |
| SCHEMBL5561218 | 0.82 | PLA2G2A (0.75) | PLA2G2APLA2G4BTP53TSHRPLA2G4A | |
| SCHEMBL6881775 | 0.81 | PLA2G2A (0.60) | PLA2G2AHTTCYP2C9CYP2C19PLA2G4B | |
| SCHEMBL4727671 | 0.80 | PLA2G2A (0.54) | PLA2G2AHTTCYP2C9CYP2C19PLA2G4B | |
| SCHEMBL2771704 | 0.80 | PLA2G2A (0.65) | PLA2G2ACYP2C9CYP2C19PLA2G4BTP53 | |
| SCHEMBL5779178 | 0.79 | CA12 (0.47) | PLA2G2ACYP2C9CYP2C19TSHRCA12 | |
| SCHEMBL2921102 | 0.78 | PDE3B (0.41) | PLA2G2AHDAC8 | |
| SCHEMBL2925424 | 0.77 | PLA2G2A (0.47) | PLA2G2APLA2G4B | |
| SCHEMBL5491044 | 0.77 | PLA2G2A (0.64) | PLA2G2APLA2G4BTP53TSHRCA12 | |
| SCHEMBL3176831 | 0.77 | CYP2C9 (0.58) | PLA2G2ACYP2C9CYP2C19PLA2G4BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46170-E1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2016-10-04 | — | — | US | disclosed |
| EP-2256130-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2013-09-25 | — | — | EP | disclosed |
| US-8476228-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2013-07-02 | — | — | US | disclosed |
| EP-1846446-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-06-26 | — | — | EP | disclosed |
| US-20120035104-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-02-09 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035104-A1 | Insulin derivatives | IAPP, INSR, GPR119 | PLA2G2A 2377/4885HTT 2608/4885CYP2C9 4333/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | PLA2G2A 2219/4885HTT 2576/4885CYP2C9 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.